Oric Pharmaceuticals
ORIC
76 hedge funds and large institutions have $98M invested in Oric Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 28 reducing their positions, and 17 closing their positions.
77% more call options, than puts
Call options by funds: $962K | Put options by funds: $543K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.55% less ownership
Funds ownership: 83.18% → 82.63% (-0.55%)
8% less funds holding
Funds holding: 83 → 76 (-7)
25% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 28
29% less capital invested
Capital invested by funds: $138M → $98M (-$39.6M)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$3.75M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$2.56M |
| 3 |
BlackRock
New York
|
+$959K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$700K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$507K |
Top Sellers
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.96M |
| 2 |
CC
Casdin Capital
New York
|
-$2.69M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$752K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$556K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$511K |
ORIC Hedge Fund Activity: Q3 2022 in Review
76 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2022, worth a combined $98M — down 29% from $138M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ORIC and 10 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 21 added.
The largest buyer was Prosight Management, opening a new position worth an estimated $3.75M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $2.96M.
- 76 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2022, down from 83 in Q2 2022.
- Funds reported $98M of Oric Pharmaceuticals stock for Q3 2022, down 29% quarter-over-quarter.
- 10 funds opened new Oric Pharmaceuticals positions in Q3 2022 and 17 closed out, a net change of -7 holders.
- The largest Oric Pharmaceuticals buyer in Q3 2022 was Prosight Management, an estimated $3.75M added.
- The largest Oric Pharmaceuticals seller in Q3 2022 was ArrowMark Colorado Holdings, an estimated $2.96M sold.
Based on aggregated 13F filings for Q3 2022.